Cancer Institute A national cancer institute
designated cancer center

Ash A. Alizadeh, MD/PhD

Publication Details

  • CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON-HODGKIN LYMPHOMA AND A THERAPEUTIC ANTIBODY TARGET THAT SYNERGIZES WITH RITUXIMAB Chao, M. P., Alizadeh, A., Tang, C. Z., Jan, M., Levy, R., Majeti, R., Weissman, I. L. ELSEVIER SCIENCE INC. 2009: S8-S9

    View details for Web of Science ID 000269396400018

Stanford Medicine Resources:

Footer Links: